Sitaglu Met 50/850mg Tablet (28s) – Comprehensive Dual Therapy
Sitaglu Met 50/850mg Tablet (28s) – Comprehensive Dual Therapy
Description
Sitaglu Met 50/850mg Tablet – Synergistic Combination for Optimal Blood Glucose Control
Sitaglu Met 50/850mg Tablet unites sitagliptin 50mg and metformin hydrochloride 850mg in a single tablet to deliver robust dual-mechanism support for adults with type 2 diabetes. Sitagliptin inhibits DPP-4 to prolong incretin effects, promoting glucose-dependent insulin secretion and reducing glucagon release, while metformin enhances insulin sensitivity and curbs hepatic glucose production. This powerful pairing achieves greater reductions in HbA1c, fasting plasma glucose, and postprandial spikes compared to either agent alone.
Designed for patients requiring intensified therapy or those transitioning to combination treatment, this twice-daily tablet simplifies regimen adherence and supports sustained glycemic control when combined with diet and exercise under medical supervision.
